Bal Pharma Past Earnings Performance
Past criteria checks 5/6
Bal Pharma has been growing earnings at an average annual rate of 49.7%, while the Pharmaceuticals industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 12.7% per year. Bal Pharma's return on equity is 11%, and it has net margins of 2.2%.
Key information
49.7%
Earnings growth rate
49.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 12.7% |
Return on equity | 11.0% |
Net Margin | 2.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price
May 30Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00
Aug 28Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 14Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 17Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00
Jul 31Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?
Aug 10Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?
Aug 10Revenue & Expenses Breakdown
How Bal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,439 | 76 | 611 | 0 |
31 Mar 24 | 3,392 | 74 | 604 | 0 |
31 Dec 23 | 3,270 | 35 | 601 | 0 |
30 Sep 23 | 3,220 | 32 | 589 | 0 |
30 Jun 23 | 3,048 | 24 | 571 | 0 |
31 Mar 23 | 3,042 | 26 | 561 | 0 |
31 Dec 22 | 2,958 | 29 | 542 | 0 |
30 Jun 22 | 2,802 | 43 | 494 | 0 |
31 Mar 22 | 2,812 | 56 | 478 | 0 |
31 Dec 21 | 2,780 | 72 | 459 | 0 |
30 Jun 21 | 2,692 | 59 | 426 | 0 |
31 Mar 21 | 2,505 | 47 | 426 | 0 |
31 Dec 20 | 2,135 | -34 | 425 | 0 |
30 Sep 20 | 1,936 | -73 | 438 | 0 |
30 Jun 20 | 1,741 | -95 | 469 | 0 |
31 Mar 20 | 1,711 | -122 | 508 | 0 |
31 Dec 19 | 1,924 | -52 | 529 | 0 |
30 Sep 19 | 2,081 | -15 | 537 | 0 |
30 Jun 19 | 2,206 | -21 | 519 | 0 |
31 Mar 19 | 2,250 | 38 | 519 | 0 |
31 Dec 18 | 2,264 | 29 | 579 | 0 |
31 Mar 18 | 2,093 | 28 | 543 | 0 |
31 Dec 17 | 2,111 | 14 | 487 | 0 |
31 Mar 17 | 2,289 | 18 | 471 | 0 |
31 Dec 16 | 2,210 | -3 | 455 | 0 |
30 Sep 16 | 2,120 | 13 | 431 | 0 |
30 Jun 16 | 2,016 | 16 | 396 | 0 |
31 Mar 16 | 1,983 | 14 | 387 | 0 |
31 Dec 15 | 1,959 | 47 | 580 | 12 |
30 Sep 15 | 1,925 | 33 | 567 | 12 |
30 Jun 15 | 1,861 | 29 | 327 | 0 |
31 Mar 15 | 1,875 | 36 | 336 | 0 |
31 Dec 14 | 1,846 | 48 | 542 | 9 |
30 Sep 14 | 1,857 | 54 | 535 | 9 |
30 Jun 14 | 1,836 | 51 | 292 | 0 |
31 Mar 14 | 1,789 | 51 | 512 | 9 |
31 Dec 13 | 1,720 | 58 | 444 | 8 |
30 Sep 13 | 1,631 | 55 | 433 | 8 |
Quality Earnings: BALPHARMA has high quality earnings.
Growing Profit Margin: BALPHARMA's current net profit margins (2.2%) are higher than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BALPHARMA has become profitable over the past 5 years, growing earnings by 49.7% per year.
Accelerating Growth: BALPHARMA's earnings growth over the past year (218.8%) exceeds its 5-year average (49.7% per year).
Earnings vs Industry: BALPHARMA earnings growth over the past year (218.8%) exceeded the Pharmaceuticals industry 18.9%.
Return on Equity
High ROE: BALPHARMA's Return on Equity (11%) is considered low.